Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin

Novo Nordisk today announced the headline results from PIONEER 8, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. The 52-week trial investigated the efficacy and safety of 3, 7 and 14 mg oral semaglutide compared https://globenewswire.com/news-release/2018/10/26/1627852/0/en/Oral-semaglutide-demonstrates-statistically-significant-reductions-in-HbA1c-and-body-weight-in-people-with-long-duration-of-type-2-diabetes-treated-with-insulin.html